Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Globus Medical ( (GMED) ).
On February 6, 2025, Globus Medical announced its acquisition of Nevro Corp. in an all-cash transaction valued at approximately $250 million, with each Nevro share priced at $5.85. This strategic acquisition, approved by both companies’ boards, aims to expand Globus Medical’s market presence and enhance its capabilities in neuromodulation and pain management technologies. Globus Medical anticipates the transaction will close by the second quarter of 2025, subject to regulatory and shareholder approvals. The acquisition aligns with Globus’s mission to grow within the musculoskeletal technology sector, potentially accelerating market penetration of Nevro’s technologies and improving financial performance to create long-term value.
More about Globus Medical
Globus Medical, based in Audubon, Pennsylvania, is a leading global musculoskeletal solutions company focused on spine, orthopedic trauma, joint reconstruction, biomaterials, and enabling technologies. Nevro Corp., headquartered in Redwood City, California, is a global medical device company specializing in solutions for chronic pain management, including the HFX spinal cord stimulation platform.
YTD Price Performance: 12.92%
Average Trading Volume: 1,045,251
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $12.58B
For detailed information about GMED stock, go to TipRanks’ Stock Analysis page.
